Karyopharm Therapeutics Inc. (KPTI) Insider Trading

Last 12 months

Insiders sold $351k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Accounting Officer Kristin Abate sold $2k on Oct 16, 20% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2023.

Net open-market

−$351k

0 buys · 21 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Sep 2023

Sep 12, 2023

Get an email when KPTI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 16	Kristin Abate Chief Accounting Officer	SoldNo plan	4,788	$0.34	$2k	20%	Form 4
Oct 1	Kristin Abate Chief Accounting Officer	SoldNo plan	378	$1.19	$450	1.6%	Form 4
Sep 1	Kristin Abate Chief Accounting Officer	SoldNo plan	19	$2.02	$38	<0.1%	Form 4
Jul 28	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	189	$7.10	$1k	0.2%	Form 4
May 14	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	403	$9.50	$4k	0.4%	Form 4
May 14	Reshma Rangwala EVP & Chief Medical Officer	SoldNo plan	408	$9.50	$4k	0.7%	Form 4
May 14	Sohanya Roshan Cheng EVP & Chief Commercial Officer	SoldNo plan	324	$9.50	$3k	0.3%	Form 4
May 14	Kristin Abate Chief Accounting Officer	SoldNo plan	53	$9.50	$504	0.2%	Form 4
May 14	Richard A. Paulson President and CEO	SoldNo plan	2,203	$9.50	$21k	0.8%	Form 4
May 14	Michael Mano EVP, CLO&Secretary	SoldNo plan	266	$9.50	$3k	0.3%	Form 4
Apr 21	Reshma Rangwala EVP & Chief Medical Officer	SoldNo plan	449	$8.94	$4k	0.8%	Form 4
Mar 2	Kristin Abate Chief Accounting Officer	SoldNo plan	559	$9.41	$5k	2.5%	Form 4
Mar 2	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	5,101	$9.41	$48k	5.1%	Form 4
Mar 2	Sohanya Roshan Cheng EVP & Chief Commercial Officer	SoldNo plan	4,604	$9.41	$43k	4.1%	Form 4
Mar 2	Michael Mano EVP, CLO&Secretary	SoldNo plan	3,526	$9.41	$33k	3.6%	Form 4
Mar 2	Reshma Rangwala EVP & Chief Medical Officer	SoldNo plan	5,066	$9.41	$48k	8.2%	Form 4
Mar 2	Richard A. Paulson President and CEO	SoldNo plan	12,361	$9.41	$116k	4.4%	Form 4
Feb 17	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	378	$8.63	$3k	0.4%	Form 4
Feb 3	Lori Macomber EVP, CFO & Treasurer	SoldNo plan	1,626	$6.30	$10k	1.9%	Form 4
Jan 28	Kristin Abate Chief Accounting Officer	SoldNo plan	50	$7.03	$352	0.2%	Form 4
Jan 21	Kristin Abate Chief Accounting Officer	SoldNo plan	265	$5.96	$2k	1.2%	Form 4
Oct 1, 2025	Kristin Abate Chief Accounting Officer	SoldNo plan	362	$6.30	$2k	3.5%	Form 4
Sep 15, 2025	Richard A. Paulson President and CEO	SoldNo plan	1,257	$6.43	$8k	1.5%	Form 4
Sep 15, 2025	Michael Mano SVP, General Counsel&Secretary	SoldNo plan	234	$6.43	$2k	1.1%	Form 4
Sep 15, 2025	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	401	$6.43	$3k	1.4%	Form 4
Sep 15, 2025	Reshma Rangwala EVP & Chief Medical Officer	SoldNo plan	408	$6.43	$3k	1.4%	Form 4
Sep 15, 2025	Sohanya Roshan Cheng EVP & Chief Commercial Officer	SoldNo plan	325	$6.43	$2k	0.9%	Form 4
Sep 15, 2025	Kristin Abate Chief Accounting Officer	SoldNo plan	23	$6.43	$148	0.2%	Form 4
Sep 3, 2025	Kristin Abate Chief Accounting Officer	SoldNo plan	12	$6.78	$81	0.1%	Form 4
Jul 29, 2025	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	191	$4.37	$835	0.7%	Form 4
Jul 22, 2025	Kristin Abate Chief Accounting Officer	SoldNo plan	238	$4.00	$952	2.5%	Form 4
May 6, 2025	Richard A. Paulson President and CEO	SoldNo plan	236	$7.12	$2k	0.3%	Form 4
Apr 23, 2025	Reshma Rangwala EVP & Chief Medical Officer	SoldNo plan	419	$6.17	$3k	1.4%	Form 4
Apr 4, 2025	Richard A. Paulson President and CEO	SoldNo plan	245	$3.74	$916	0.3%	Form 4
Mar 4, 2025	Sohanya Roshan Cheng EVP & Chief Commercial Officer	SoldNo plan	3,445	$6.29	$22k	9.1%	Form 4
Mar 4, 2025	Richard A. Paulson President and CEO	SoldNo plan	11,694	$6.29	$74k	12%	Form 4
Mar 4, 2025	Reshma Rangwala EVP & Chief Medical Officer	SoldNo plan	3,587	$6.29	$23k	11%	Form 4
Mar 4, 2025	Stuart Poulton EVP, Chief Development Officer	SoldNo plan	3,548	$6.29	$22k	11%	Form 4
Mar 4, 2025	Kristin Abate Chief Accounting Officer	SoldNo plan	571	$6.29	$4k	5.6%	Form 4
Mar 4, 2025	Michael Mano SVP, General Counsel&Secretary	SoldNo plan	2,793	$6.29	$18k	12%	Form 4

Oct 16No plan
Kristin Abate
Chief Accounting Officer · sold 4,788 at $0.34
$2k
20% of stake
Oct 1No plan
Kristin Abate
Chief Accounting Officer · sold 378 at $1.19
$450
1.6% of stake
Sep 1No plan
Kristin Abate
Chief Accounting Officer · sold 19 at $2.02
$38
<0.1% of stake
Jul 28No plan
Stuart Poulton
EVP, Chief Development Officer · sold 189 at $7.10
$1k
0.2% of stake
May 14No plan
Stuart Poulton
EVP, Chief Development Officer · sold 403 at $9.50
$4k
0.4% of stake
May 14No plan
Reshma Rangwala
EVP & Chief Medical Officer · sold 408 at $9.50
$4k
0.7% of stake
May 14No plan
Sohanya Roshan Cheng
EVP & Chief Commercial Officer · sold 324 at $9.50
$3k
0.3% of stake
May 14No plan
Kristin Abate
Chief Accounting Officer · sold 53 at $9.50
$504
0.2% of stake
May 14No plan
Richard A. Paulson
President and CEO · sold 2,203 at $9.50
$21k
0.8% of stake
May 14No plan
Michael Mano
EVP, CLO&Secretary · sold 266 at $9.50
$3k
0.3% of stake
Apr 21No plan
Reshma Rangwala
EVP & Chief Medical Officer · sold 449 at $8.94
$4k
0.8% of stake
Mar 2No plan
Kristin Abate
Chief Accounting Officer · sold 559 at $9.41
$5k
2.5% of stake
Mar 2No plan
Stuart Poulton
EVP, Chief Development Officer · sold 5,101 at $9.41
$48k
5.1% of stake
Mar 2No plan
Sohanya Roshan Cheng
EVP & Chief Commercial Officer · sold 4,604 at $9.41
$43k
4.1% of stake
Mar 2No plan
Michael Mano
EVP, CLO&Secretary · sold 3,526 at $9.41
$33k
3.6% of stake
Mar 2No plan
Reshma Rangwala
EVP & Chief Medical Officer · sold 5,066 at $9.41
$48k
8.2% of stake
Mar 2No plan
Richard A. Paulson
President and CEO · sold 12,361 at $9.41
$116k
4.4% of stake
Feb 17No plan
Stuart Poulton
EVP, Chief Development Officer · sold 378 at $8.63
$3k
0.4% of stake
Feb 3No plan
Lori Macomber
EVP, CFO & Treasurer · sold 1,626 at $6.30
$10k
1.9% of stake
Jan 28No plan
Kristin Abate
Chief Accounting Officer · sold 50 at $7.03
$352
0.2% of stake
Jan 21No plan
Kristin Abate
Chief Accounting Officer · sold 265 at $5.96
$2k
1.2% of stake
Oct 1, 2025No plan
Kristin Abate
Chief Accounting Officer · sold 362 at $6.30
$2k
3.5% of stake
Sep 15, 2025No plan
Richard A. Paulson
President and CEO · sold 1,257 at $6.43
$8k
1.5% of stake
Sep 15, 2025No plan
Michael Mano
SVP, General Counsel&Secretary · sold 234 at $6.43
$2k
1.1% of stake
Sep 15, 2025No plan
Stuart Poulton
EVP, Chief Development Officer · sold 401 at $6.43
$3k
1.4% of stake
Sep 15, 2025No plan
Reshma Rangwala
EVP & Chief Medical Officer · sold 408 at $6.43
$3k
1.4% of stake
Sep 15, 2025No plan
Sohanya Roshan Cheng
EVP & Chief Commercial Officer · sold 325 at $6.43
$2k
0.9% of stake
Sep 15, 2025No plan
Kristin Abate
Chief Accounting Officer · sold 23 at $6.43
$148
0.2% of stake
Sep 3, 2025No plan
Kristin Abate
Chief Accounting Officer · sold 12 at $6.78
$81
0.1% of stake
Jul 29, 2025No plan
Stuart Poulton
EVP, Chief Development Officer · sold 191 at $4.37
$835
0.7% of stake
Jul 22, 2025No plan
Kristin Abate
Chief Accounting Officer · sold 238 at $4.00
$952
2.5% of stake
May 6, 2025No plan
Richard A. Paulson
President and CEO · sold 236 at $7.12
$2k
0.3% of stake
Apr 23, 2025No plan
Reshma Rangwala
EVP & Chief Medical Officer · sold 419 at $6.17
$3k
1.4% of stake
Apr 4, 2025No plan
Richard A. Paulson
President and CEO · sold 245 at $3.74
$916
0.3% of stake
Mar 4, 2025No plan
Sohanya Roshan Cheng
EVP & Chief Commercial Officer · sold 3,445 at $6.29
$22k
9.1% of stake
Mar 4, 2025No plan
Richard A. Paulson
President and CEO · sold 11,694 at $6.29
$74k
12% of stake
Mar 4, 2025No plan
Reshma Rangwala
EVP & Chief Medical Officer · sold 3,587 at $6.29
$23k
11% of stake
Mar 4, 2025No plan
Stuart Poulton
EVP, Chief Development Officer · sold 3,548 at $6.29
$22k
11% of stake
Mar 4, 2025No plan
Kristin Abate
Chief Accounting Officer · sold 571 at $6.29
$4k
5.6% of stake
Mar 4, 2025No plan
Michael Mano
SVP, General Counsel&Secretary · sold 2,793 at $6.29
$18k
12% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KPTI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

ELTPElite Pharmaceuticals Inc.

HRTXHeron Therapeutics Inc.

ZVRAZevra Therapeutics, Inc.

DAWNDay One Biopharmaceuticals, Inc.

NUVBNuvation Bio Inc.

RCUSArcus Biosciences Inc.

SPRYArs Pharmaceuticals Inc

GYREGyre Therapeutics Inc.

Spot a number that looks wrong? Check it in KPTI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KPTI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.